AbbVie (ABBV) Presents Lung Cancer Data at WCLC 2026 Conference
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowAbbVie (ABBV) presented lung cancer data at the World Conference on Lung Cancer (WCLC) 2026, including results for ABBV-1480, which achieved a 90.0% objective response rate in squamous NSCLC and 75.9% in non-squamous NSCLC when combined with platinum-based chemotherapy. Safety data for ABBV-706 showed nausea in 35.8% of patients and grade 3+ pneumonitis or interstitial lung disease in 1.7% of patients.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About AbbVie Inc. (ABBV)
AbbVie is a research-based pharmaceutical company with a portfolio spanning immunology, oncology, and neuroscience.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABBV news
- AbbVie Expects $12.7 Billion in Neuroscience Sales This Year
- AbbVie (ABBV) Stock Declines Amid Market Uncertainty
- AbbVie (ABBV) Trims 2026 Profit Forecast Following Apogee Acquisition
- JPMorgan Recommends Eli Lilly, AbbVie, Danaher as Top Healthcare Stocks
- AbbVie (ABBV) Stock May Move 4.2% on July 31 Earnings Report
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
